If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 36 Similar Profiles
Fetal Blood Medicine & Life Sciences
Mesenchymal Stromal Cells Medicine & Life Sciences
Cell- and Tissue-Based Therapy Medicine & Life Sciences
Natural Killer Cells Medicine & Life Sciences
Stem Cells Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Cryopreservation Medicine & Life Sciences
Transplantation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1997 2024

Intima process qualification TILs

McKenna, D. H.

INTIMA CAPITAL, LLC

5/15/197/15/19

Project: Research project

Cell- and Tissue-Based Therapy
Natural Killer Cells
Prostatic Neoplasms

Research Output 2002 2019

Cell therapies for trauma and critical care medicine: critical issues in translation for cellular and novel therapies in trauma and critical care

Stroncek, D. F., Mathew, A. J. & McKenna, D. H., Feb 1 2019, In : Transfusion. 59, p. 854-857 4 p.

Research output: Contribution to journalArticle

Critical Care
Cell- and Tissue-Based Therapy
Medicine
Wounds and Injuries
Therapeutics
1 Citation (Scopus)

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger, K., Yu, G., McKenna, D. H. & Hubel, A., Jun 1 2019, In : Transfusion Medicine and Hemotherapy. 46, 3, p. 188-196 9 p.

Research output: Contribution to journalReview article

Colony-Forming Units Assay
Cryopreservation
Hematopoietic Stem Cells
Technology
Cell- and Tissue-Based Therapy
Open Access
Adoptive Immunotherapy
Natural Killer Cells
Leukemia
Bone Marrow
Cell Count
14 Citations (Scopus)

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Matthay, M. A., Calfee, C. S., Zhuo, H., Thompson, B. T., Wilson, J. G., Levitt, J. E., Rogers, A. J., Gotts, J. E., Wiener-Kronish, J. P., Bajwa, E. K., Donahoe, M. P., McVerry, B. J., Ortiz, L. A., Exline, M., Christman, J. W., Abbott, J., Delucchi, K. L., Caballero, L., McMillan, M., McKenna, D. H. & 1 othersLiu, K. D., Feb 1 2019, In : The Lancet Respiratory Medicine. 7, 2, p. 154-162 9 p.

Research output: Contribution to journalArticle

Severe Acute Respiratory Syndrome
Adult Respiratory Distress Syndrome
Mesenchymal Stromal Cells
Safety
Therapeutics
1 Citation (Scopus)
Open Access
Natural Killer Cells
Immunotherapy
Interleukin-15
Interleukin-2
B-Lymphocytes